Securities Fraud Investigations
Pomerantz LLP Launches Securities Fraud Investigations Into Five Major Public Companies
Anonymous
Key Points
1
Baidu was reportedly slated for addition to a Pentagon list of companies deemed to aid the Chinese military; its American depositary shares fell 1.3% after the news on Nov. 26, 2025.
2
Baidu’s management said it was “deliberately holding back on monetizing the AI search,” while warning that competition for users’ time and attention had intensified further; the company’s ADS price fell 12.73% on Aug. 18, 2026.
3
Dr. Reddy’s CEO Erez Israeli said semaglutide-related challenges included lower sales, provisions for rejected batches, the loss of production-linked incentives and other associated costs, which adversely affected the quarter’s EBITDA margin.
4
D-Wave’s second-quarter 2026 revenue was $3.08 million, slightly below $3.1 million a year earlier and well below analysts’ expectations of approximately $4.03 million to $4.08 million; its stock fell 9.28% after the report.
5
JinkoSolar’s April 2026 results were described as inconsistent with statements made by company officers during the Nov. 17, 2025 earnings call, after a non-cash impairment charge exceeding $200 million contributed to a $214.5 million GAAP loss.
Pomerantz LLP announced investigations into five companies accused of securities fraud following sharp stock declines tied to company-specific failures. Pomerantz is examining whether Baidu, Dr. Reddy's Laboratories, D-Wave Quantum, OSI Systems, and JinkoSolar—along with certain officers and directors—engaged in unlawful business practices that misled investors about financial performance and competitive challenges.
The investigations span AI monetization delays at Baidu, manufacturing setbacks at Dr. Reddy's, missed revenue targets at D-Wave, delayed product shipments at OSI Systems, and a massive impairment charge at JinkoSolar. Each case centers on a gap between what company leaders told investors and the actual financial results that followed.
Baidu Faces Pentagon List Threat and AI Monetization Concerns
Baidu's American Depositary Shares fell 1.3% on November 26, 2025, after news that the company was reportedly slated for addition to a Pentagon list of firms deemed to aid the Chinese military. Pomerantz is investigating whether this geopolitical risk was properly disclosed to investors before the stock decline.
Months later, Baidu disclosed another problem: management was "deliberately holding back on monetizing the AI search," according to company statements. The ADS price plummeted 12.73% on August 18, 2026, as management also warned that competition for users' time and attention had intensified. Investors claim they were not warned about the delay in AI revenue generation.
Dr. Reddy's Semaglutide Production Crisis Crushes Margins
Dr. Reddy's Laboratories saw its stock drop as the company revealed major semaglutide-related challenges that crushed profitability. CEO Erez Israeli disclosed that lower sales, provisions for rejected batches, loss of production-linked incentives, and other associated costs adversely affected the quarter's EBITDA margin, according to company disclosures.
Pomerantz is investigating whether Dr. Reddy's officers adequately warned investors about manufacturing and regulatory risks tied to the semaglutide business before these hits to earnings materialized. The batch rejections and lost incentives suggest quality or compliance problems that should have been flagged earlier.
D-Wave's Quantum Computing Revenue Falls Far Short of Expectations
D-Wave Quantum reported second-quarter 2026 revenue of $3.08 million, barely above the prior year's $3.07 million and far below analyst expectations of $4.03 million to $4.08 million. The stock fell 9.28% after the disappointing report, and the company's CFO resigned around the same time, according to Pomerantz.
Pomerantz is examining whether D-Wave's management misled investors about the pace of quantum computing adoption and revenue trajectory. The massive gap between guidance and results—a 30% shortfall on some estimates—raises questions about what executives knew and when they knew it.
OSI Systems and JinkoSolar Caught Between Guidance and Reality
OSI Systems' shares fell after the company reported revenue below expectations due to deferred product deliveries caused by site constraints. The company had not adequately signaled to investors that facility limitations would delay shipments, Pomerantz alleges, leaving shareholders exposed to surprise downside.
JinkoSolar's stock collapsed after a non-cash impairment charge exceeding $200 million contributed to a $214.5 million GAAP loss. April 2026 results contradicted statements made by company officers during the November 17, 2025 earnings call, according to Pomerantz. Weaker-than-expected revenue, declining margins, and solar market pressure followed, suggesting executives misrepresented the business outlook just months earlier.
Sentiment
Mostly NegativeNEGATIVENEUTRALPOSITIVE
Publishers
17
Articles
97
Reach
114
A
AnonymousAuthor
